Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HWK-016 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on HWK-016, a putative antibody-drug conjugate (ADC) targeting MUC16 (Mar 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HWK-016 | HWK 016|HWK016 | MUC16 Targeted Therapy 11 | Limited information is currently available on HWK-016, a putative antibody-drug conjugate (ADC) targeting MUC16 (Mar 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07470853 | Phase I | HWK-016 Bevacizumab + HWK-016 | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Recruiting | USA | 0 |